Skip to main content
. 2018 Aug 22;10(2):408–417. doi: 10.1111/jdi.12900

Figure 1.

Figure 1

Cumulative incidence of nausea/vomiting caused by glucagon‐like peptide‐1 receptor agonists in type 2 diabetes patients. (a) Total (b) with or without treatment with proton pump inhibitors (PPIs) or histamine‐2 receptor antagonists (H2RAs), PPIs or H2RAs (+), PPIs or H2RAs (−). Cumulative incidence of nausea/vomiting was determined using the Fine–Gray method. The P‐value was determined using Gray's test.